Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
WALTHAM, Mass., Feb. 27, 2017 -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced its planned participation in three upcoming investor conferences. The details for the three conferences are:
- The Cowen and Company 37th Annual Health Care Conference at the Boston Marriott Copley Place on March 6, 2017. Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will make a presentation at 3:20 pm ET.
- The 29th Annual ROTH Conference at the Ritz Carlton Hotel in Orange County, California on March 13, 2017. Michael A. Metzger, President and Chief Operating Officer of Syndax, will make a presentation at 4:30 pm PT.
- The Oppenheimer 27th Annual Healthcare Conference at the Westin New York Grand Central on March 22, 2017. Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will make a presentation at 10:20 am ET.
A live webcast of these presentations can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the events will also be available for a limited time.
About Syndax Pharmaceuticals, Inc.
Syndax is a clinical stage biopharmaceutical company focused on developing an innovative pipeline of combination therapies in multiple cancer indications. Our lead product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from our Phase 2b clinical trial, ENCORE 301, is currently being evaluated in a Phase 3 clinical trial for advanced hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer. Syndax is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase 1b/2 clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma; with Genentech, Inc. for TNBC; and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer. SNDX-6352 is being evaluated in a single ascending dose Phase 1 clinical trial and is expected to be developed to treat a variety of cancers. For more information on Syndax, please visit www.syndax.com.
Investor Contacts Heather Savelle Argot Partners [email protected] Tel 646.395.3734 Media Contact Eliza Schleifstein Argot Partners [email protected] Tel 973.361.1546
